论文部分内容阅读
美国Pannacos公司研发的首个HIV突变抑制剂PA-457的Ⅱa期临床试验初步数据显示,该药物可将基线的HIV载量减少90％。公司计划于2006年上半年开展Ⅱb期临床试验。PA-457作为突变抑制剂的作用机制与已获准
Preliminary data from Phase IIa trials of PA-457, the first HIV mutation inhibitor developed by Pannacos in the United States, showed that the drug reduced baseline HIV load by 90%. The company plans to carry out phase Ⅱ b clinical trials in the first half of 2006. The mechanism of action of PA-457 as a mutator inhibitor has been approved